TY - JOUR
T1 - Advances in the biology and therapy of chronic myeloid leukemia
T2 - Proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
AU - Van Etten, Richard A.
AU - Mauro, Michael
AU - Radich, Jerald P.
AU - Goldman, John M.
AU - Saglio, Giuseppe
AU - Jamieson, Catriona
AU - Soverini, Simona
AU - Gambacorti-Passerini, Carlo
AU - Hehlmann, Rüdiger
AU - Martinelli, Giovanni
AU - Perrotti, Danilo
AU - Scadden, David T.
AU - Skorski, Tomasz
AU - Tefferi, Ayalew
AU - Mughal, Tariq I.
N1 - Funding Information:
This Workshop and related activities were made possible by an unrestricted educational grant from Incyte Corporation, and by the Alpine Oncology Foundation who received unrestricted support from Sanofi Oncology, Bristol-Myers Squibb and YM Bioscience. Special thanks go to Alpa Parmar and Susannne Blassingale for their help, and to the Postgraduate Institute for Medicine for CME accreditation. Preparation of this manuscript was supported in part by NIH grants CA0905756 to R.A.V. and CA134458 and CA123014 to T.S.
PY - 2013/6
Y1 - 2013/6
N2 - Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.
AB - Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.
KW - Chronic myelogenous leukemia
KW - Dasatinib
KW - Imatinib mesylate
KW - Nilotinib
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84877787719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877787719&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.745524
DO - 10.3109/10428194.2012.745524
M3 - Review article
C2 - 23121619
AN - SCOPUS:84877787719
SN - 1042-8194
VL - 54
SP - 1151
EP - 1158
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -